Yelena Y. Janjigian MD presents DESTINY-Gastric03 at #ESMO24 #ESMOAmbassadors ESMO - Eur. Oncology Filippo Pietrantonio #TaniaFleitas

ESMO - Eur. Oncology Sherene Loi, MD presents data on young patients treated with #ribociclib in Natalee  #ESMO24 #ESMOAmbassadors

Durante #ESMO24 ESOncology lancia un progetto di valorizzazione del contributo europeo all’evoluzione in #oncologia: Oncopedia. Scoprilo qui: medinews.it/comunicati/onc… ESMO - Eur. Oncology Francesco Perrone Silvio Monfardini

The Royal Marsden NHS Foundation Trust UroToday.com Gil Morgan, MD OncoAlert ESMO - Eur. Oncology Neeraj Agarwal, MD, FASCO Derya Tilki, MD Axel S. Merseburger Deborah Mukherji Yüksel Ürün Tian Zhang, MD, MHS Now up the incomparable Misha Beltran highlighting DLL-3 as critical target in neuroendocrine #ProstateCancer ESMO - Eur. Oncology #ESMO24 UroToday.com OncoAlert Gil Morgan, MD

MD Anderson Cancer Center is present at #ESMO24!!!!! What a nice surprise 🥰 and nobody better than Lany Kimmons to represent the Cancer Network!!!! Happy to see you!!! MD Anderson Madrid

Hear Elise Nassif Haddad, of MD Anderson Cancer Center, preview her #ESMO2024 presentation on Gp100 in clear cell sarcomas! And see our site for more from the meeting! ESMO - Eur. Oncology #ESMO24 #scmsm onclive.com/conference/esm…

Much interest in #bladder cancer at the lunchtime symposium. Even the overflow area is full!!! 💙alison birtle starts off with navigating first line treatments in advanced disease. ESMO - Eur. Oncology #ESMO24

Breastfeeding was found safe and feasible after breast cancer diagnosis, according to two studies presented at #ESMO24. Dana-Farber's Ann Partridge, MD, MPH, (Ann Partridge MD, MPH) details the findings in this video.

Dr. Helena Linardou sets the stage at the #ESMOforWomen session ESMO - Eur. Oncology #ESMO24

Promising results for BRAFV600E mCRC patients. Breakwater SLI cohort 3 results Josep Tabernero #ESMO24 ESMO - Eur. Oncology

Another fantastic interview with Nabil Saba, MD of Winship Cancer Institute of Emory University. He told us all about an ECOG-ACRIN Cancer Research Group trial examining chemo followed by surgery and PORT vs surgery and PORT for organ preservation of T3 & T4a (selected T4b) sinonasal SNC. onclive.com/conference/esm… ESMO - Eur. Oncology #ESMO24

Insightful & great talk by superstar Misha Beltran ESMO - Eur. Oncology #ESMO24 #ESMOAmbassadors OncoAlert

Awesome discussion of Prof Harter in ESMO - Eur. Oncology #ESMO24 !!!!

$Smmt #Akeso ivonescimab +/- aCD47 + chemo triplet FOLFOXIRI in 1L mCRC #esmo24 discussant slides 3/x The speaker reckons the Immunoscore IC is pot the best biomarker, to be tested in ATEZOtribe 2 Ivo combo numerically OK but hard to interpret Ph3 already started by Akeso!

Tips for #ESMO24 - Need some quiet time to recharge, head to the first floor close to hall 6 - Good Chai Latte at the MSD booth - Coffee ☕️ - head over to Boehringer Ingelheim - Free AACR membership for attendees - Stay hydrated - Avoid peak times at the food court

.Hina Khan, using a large 🇺🇸 dataset, outlines racial differences across irAEs in patients with lung cancer. 🎯 This is why diversity in clinical trial accrual matters! OncoAlert #lcsm #ESMO24

Searching better and faster models for drug development and use optimization at #ESMO24 OncoAlert

🚨 #PRODIGE44 - preop radiation for LA-BR-PDAC Phase 2 of👥110 pts Preop mFOLFIRINOX + rads🆚no rads ❌No difference R0 ❌No difference OS or PFS #ESMO24 really hitting nail in⚰️of neoadj rads in GI cancers 🎉Great news: close 50 months median OS with resection after NAT!

ENGOT-cx11/GOG-3047/KEYNOTE-A18 Phase 3 Trial: Pembrolizumab + Chemoradiotherapy in advanced cervical cancer shows improved OS (HR 0.67) & PFS (HR 0.68) vs. placebo. A promising step forward in treatment! #Cancer #Oncology OncoAlert ESGO ESMO - Eur. Oncology #ESMO24

It still frustrates me that most often these patients are excluded from #TNBC trials....they behave like TNBC not ER+! #access #underserved #ERlow #ESMO24 #ESMOAmbassadors